No abstract

No abstract

Candida albicans is the most common cause of fungal infections worldwide. Infection by C. albicans is closely associated with its ability to form a biofilm, closely packed communities of cells attached to the surfaces of human tissues and implanted devices, in or on the host. When tested for susceptibility to antifungals, such as polyenes, azoles, and allylamines, C. albicans cells in a biofilm are more resistant to antifungal agents than C. albicans cells in the planktonic form. Cyclic Adenosine monophosphate (cAMP) is one of the key elements for triggering hyphal and biofilm formation in C. albicans. It is hard to detect or extract molecular markers (e.g., cAMP) from C. albicans biofilms because the biofilms have a complex three-dimensional architecture with an extracellular matrix surrounding the cell walls of the cells in the biofilm. Here, we present an improved protocol that can effectively measure the level of intracellular cAMP in C. albicans biofilms.

Background: Farnesol enhances the susceptibility of Candida albicans biofilms to antifungals, while the molecular mechanisms of this behavior are poorly understood. RAS1 regulates the hyphal growth of C. albicans, and farnesol inhibited hyphal growth by RAS1 regulation, while the role of RAS1 in the resistance of C. albicans biofilms and the molecular mechanism of the RAS1 in the farnesol-relevant antifungal capacity to C. albicans biofilms is still unknown. The study hypothesized that Ras1 involved in the antifungal resistance of C. albicans and the inhibition of farnesol on the resistance of biofilms. Results: The susceptibility assays showed that RAS1 over-expressing strain (RAS1OE) increased the resistance of C.albicans in both planktonic and biofilm form to antifungals, while RAS1 deletion strain (ras1Δ/Δ) reduced that to antifungals. The SMIC50 of the antifungals were increased with the mature of the biofilms formed from the mutant and the wild strains. Exogenous farnesol decreased the resistance of RAS1OE to antifungals, including fluconazole, amphotericin B, itraconazole, caspofungin, terbinafine, 5-flurocytosine and nystatin. The inhibitory effects of farnesol on the antifungal resistance of the biofilms from the RAS1OE were in accordance to almost all of the growth phases. Moreover, exogenous farnesol decreased the resistance of biofilms from RAS1OE more obviously than that from the wild strains (P<0.05). In addition, Morphological observation showed that that RAS1OE increased hyphal growth the biofilms, while ras1Δ/Δ reduced that of the biofilms. Compare to the wild-type strain, the inhibitory effects of farnesol on hyphal growth were more obvious to the RAS1OE, while less obvious to the ras1Δ/Δ. Furthermore, farnesol reduced the level of Ras1 and the expression of RAS1 of the biofilms formed from the RAS1OE strain compared with those of the untreated controls at all studied phases. Moreover, farnesol reduced the level of Ras1 and the expression of RAS1 of the biofilms formed from RAS1OE more obviously than that from the wild strains. Conclusions: Ras1 involved in the antifungal resistance of Candida albicans, and the inhibition of farnesol on the resistance of biofilm.